Diagnostics And Consultancy Center Sveti Georgi EOOD
- Address
- lock Available on a paid plan
Immune System Diseases
At Diagnostics And Consultancy Center Sveti Georgi EOOD in Haskovo, Bulgaria, clinical research in immune system diseases focuses on conditions that cause ongoing inflammation and immune-driven skin symptoms. The studies are mainly designed to test new treatment options and compare them with existing care for better disease control.
- Chronic spontaneous urticaria and chronic urticaria
- Systemic lupus erythematosus and cutaneous lupus erythematosus
- Evaluation of new therapies for symptom reduction and improved disease activity control
- Comparison with established treatments to assess effectiveness in everyday clinical use
These trials aim to improve options for people living with persistent immune-related skin and autoimmune conditions, with a strong emphasis on finding therapies that can better manage flare-ups and long-term disease burden.
Skin and Connective Tissue Diseases
Research in skin and connective tissue diseases at this site centers on inflammatory disorders that affect the skin and can also involve broader autoimmune activity. The main goal is to evaluate whether investigational treatments can reduce visible skin disease and improve patient outcomes.
- Moderate to severe plaque psoriasis
- Primary discoid lupus erythematosus
- Subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus
- Testing new therapies for skin disease activity and treatment response
- Assessing safety, tolerability, and longer-term benefit in chronic dermatologic conditions
The clinical trial portfolio reflects a clear interest in advancing care for patients with difficult-to-treat skin diseases, especially those with autoimmune causes and ongoing symptoms despite standard treatment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Biogen Idec Research Limited1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostics And Consultancy Center Sveti Georgi EOOD
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of Efficacy and Safety of BP11 and EU-Approved Omalizumab in Chronic Spontaneous Urticaria Resistant to H1 Antihistamines | Curateq Biologics Private Limited | Phase III | Not Recruiting | Sep 2023 | Mar 2026 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 3 | Unknown | 2024-05-07 | 2025-09-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.